Board Member
Bristol Myers Squibb Co (BMY)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
Christopher Boerner, Ph.D. is recorded as CEO, Board Member and COO at Bristol Myers Squibb Co (BMY). Bristol Myers Squibb Co reported in an 8-K filed April 26, 2023 that Christopher Boerner, Ph.D. was appointed Chief Executive Officer, effective November 1, 2023. Bristol Myers Squibb Co reported in an 8-K filed April 26, 2023 that Christopher Boerner, Ph.D. was appointed Chief Operating Officer, effective April 26, 2023. Christopher Boerner, Ph.D. has spoken on 2 earnings calls across 1 company, most recently for Bristol Myers Squibb Co on July 30, 2026.
“Christopher Boerner, PhD, EVP, Chief Commercialization Officer, has been named EVP, Chief Operating Officer, effective immediately, and will succeed Caforio as CEO on November 1, 2023.”
“on April 21, 2023, the Board appointed Christopher Boerner, Ph.D., to serve as the Company's Chief Operating Officer, effective April 26, 2023”
Summary generated from SEC filings and earnings-call records held by Equibles.
Recorded current and former roles; source labels appear when available.
2023-11-01–present
2023-05-02–present
2023-04-26–present
Recorded roles and call appearances connecting this person to public companies.
CEO, Board Member, COO
2023-04-26–present
Other people whose current roles at this company are on record from its filings.
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.
